12 October 2023  
EMA/454102/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Prevymis 
letermovir 
On 12 October 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Prevymis. The marketing authorisation holder for this medicinal product is Merck Sharp & Dohme B.V. 
The CHMP adopted a new indication for prevention of CMV disease in seronegative adults who received a 
kidney transplant from a CMV-seropositive donor. For information, the full indications for Prevymis will be 
as follows:2 
PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in 
adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant 
(HSCT). 
PREVYMIS is indicated for prophylaxis of CMV disease in CMV-seronegative adults who 
have received a kidney transplant from a CMV-seropositive donor [D+/R-]. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union  
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
